Lilly's (LLY.US) IL-23 inhibitor, Omvoh, showed long-term efficacy in ulcerative colitis and Crohn's disease trials

Lilly (LLY.US) on Monday announced the results of a study showing that Mirikizumab (brand name Omvoh) has long-term efficacy in ulcerative colitis (UC) and Crohn's disease.

The drugmaker claimed that Omvoh is the first and only IL-23p19 inhibitor to report long-term, multi-year, sustained efficacy and safety in both diseases, according to results from two Phase 3 studies in patients with moderate to severe active UC and Crohn's disease.

In the UC study, 81% of patients maintained long-term clinical remission after three years of treatment, and 82% achieved long-term endoscopic remission.

In the Crohn's disease study, 87% of patients achieved clinical remission and 54% achieved endoscopic remission.

It is known that Omvoh was approved by the US Food and Drug Administration (FDA) in October 2023 as the first drug in its class for the treatment of adult UC. The drug has also been approved in 44 countries worldwide. Lilly is currently seeking approval for Crohn's disease in the US, Canada, Europe, Japan and China, and plans to submit more global regulatory filings.

Earlier this month, Lilly also reported positive data from a Phase 3 study that compared its drug to Johnson & Johnson's (JNJ.US) Stelara in treating Crohn's disease.